VeonGen Reports Promising Clinical Progress for Stargardt Disease Gene Therapy

VeonGen Therapeutics has announced encouraging clinical progress for VG801, an investigational gene therapy for ABCA4-associated retinal diseases, including Stargardt disease, with results to be presented at the prestigious ARVO 2026 conference in Denver this May. Importantly, VG801 has demonstrated a favorable safety profile with no dose-limiting or serious adverse events reported to date in both adult and pediatric patients.

In the ongoing Phase 1/2 study, patients treated with VG801 showed consistent improvements in vision that have been sustained through six- and twelve-month follow-up periods as measured by best-corrected visual acuity (BCVA)—the gold standard measure of central vision clarity. Additionally, patients demonstrated improvements using a newly developed Virtual Reality Visual Test (VRVT), which provides a more comprehensive assessment of functional vision in real-world scenarios.

VG801 represents a significant advancement in Stargardt disease treatment. Using VeonGen's proprietary dual-AAV gene therapy platform, VG801 delivers a full-length functional copy of the ABCA4 gene directly to photoreceptor cells in the retina. This approach has the potential to address the underlying genetic cause of all forms of ABCA4-associated Stargardt disease, regardless of the specific mutation.

Stargardt disease is the most common inherited retinal disorder, affecting approximately 1 in 8,000-10,000 individuals worldwide. Caused by mutations in the ABCA4 gene, the condition typically begins in childhood or adolescence with progressive central vision loss that can lead to legal blindness. Currently, no approved treatments exist for this condition.

VG801 has received significant regulatory support, including FDA Regenerative Medicine Advanced Therapy (RMAT) designation and participation in the FDA's Rare Disease Endpoint Advancement (RDEA) pilot program. These designations support enhanced regulatory interactions and potentially accelerated development pathways.

The innovative VRVT assessment tool has been accepted into the FDA's RDEA program, supporting its development as a novel endpoint for measuring functional vision improvements in future pivotal trials.

Foundation Fighting Blindness is committed to funding cutting-edge research that helps advance promising treatments from early-stage development through clinical trials.